MedTrace Logo

3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma

NCT02057445 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-12-22

No results posted yet for this study

Summary

The administration of allogeneic third party derived LMP specific-CTLs (special peripheral blood cells from another person) that are made specific to fight EBV infection) in Children, Adolescents and Young Adults (CAYA) with EBV-associated refractory or relapsed lymphoma will be feasible ( able to be done), safe and well tolerated (no unexpected serious events will occur). In addition, potential donors who are EBV positive will be enrolled to donate peripheral blood to help build a bank of these specific EBV fighting cell lines.

Conditions

  • Non-Hodgkins Lymphoma
  • Hodgkins Lymphoma
  • Lymphoproliferative Disorder

Interventions

DRUG

EBV CTL's

Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.

OTHER

Peripheral Blood Donor

Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.

Sponsors & Collaborators

  • Children's National Research Institute

    collaborator OTHER

  • Baylor College of Medicine

    collaborator OTHER

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • University of Michigan

    collaborator OTHER

  • University of Utah

    collaborator OTHER

  • City of Hope Medical Center

    collaborator OTHER

  • Ohio University

    collaborator OTHER

  • Johns Hopkins University

    collaborator OTHER

  • New York Medical College

    lead OTHER

Principal Investigators

  • Mitchell Cairo, MD · New York Medical College

  • Catherine Bollard, MD · Children's National Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02057445 on ClinicalTrials.gov